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ABSTRACT 24 
The wide phenotypic variability of prion diseases is thought to depend on the interaction of a 25 
host genotype with prion strains that have self-perpetuating biological properties enciphered in 26 
distinct conformations of the misfolded prion protein, PrPSc. The latter concept is largely based 27 
on indirect approaches studying the effect of proteases or denaturing agents on the 28 
physicochemical properties of PrPSc aggregates. Furthermore, most data come from studies on 29 
rodent-adapted prion strains, making current understanding of the molecular basis of strains and 30 
phenotypic variability in naturally occurring diseases, especially in humans, more limited. To fill 31 
this gap, we studied the effect of guanidine hydrochloride (GdnHCl) and heating on PrPSc 32 
aggregates extracted from 60 sporadic CJD and 6 variant CJD brains. While denaturation curves 33 
obtained after exposure of PrPSc to increasing GndHCl concentrations showed a similar profile 34 
among the 7 CJD types analysed, PrPSc exposure to increasing temperature revealed significantly 35 
different and type-specific responses. In particular, MM1 and VV2, the most prevalent and faster 36 
replicating CJD types, showed stable and highly resistant PrPSc aggregates, whereas VV1, a rare 37 
and slow propagating type, revealed unstable aggregates that easily dissolved at low temperature. 38 
Taken together our results indicate that the molecular interactions mediating the aggregation 39 
state of PrPSc, possibly enciphering strain diversity, are differently targeted by GdnHCl, 40 
temperature and proteases. Furthermore, the detected positive correlation between thermo-41 
stability of PrPSc aggregates and disease transmission efficiency makes inconsistent the proposed 42 
hypothesis that a decrease in conformational stability of prions results in an increase in their 43 
replication efficiency.  44 
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IMPORTANCE 45 
Prion strains are defined as infectious isolates propagating distinctive phenotypic traits after 46 
transmission to syngenic hosts. Although the molecular basis of prion strains is not fully 47 
understood, it is largely accepted that variations in prion protein conformation drive the 48 
molecular changes leading to the different phenotypes. In this study, we exposed abnormal prion 49 
protein aggregates, encompassing the spectrum of human prion strains, to both guanidine 50 
hydrochloride and thermal unfolding. Remarkably, while exposure to increasing temperature 51 
revealed significant strain-specific differences in the denaturation profile of the protein, 52 
treatment with guanidine hydrochloride did not. The findings suggest that thermal and chemical 53 
denaturation perturb the structure of prion protein aggregates differently. Moreover, since the 54 
most thermo-stable prion protein types were those associated with the most prevalent phenotypes 55 
and most rapidly and efficiently transmitting strains, the results suggest a direct correlation 56 
between the strain replication efficiency and the thermo-stability of prion protein aggregates.57 
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INTRODUCTION 58 
Prion diseases are invariably fatal neurodegenerative disorders of humans and other mammals, 59 
characterized by tissue deposition of aggregates of a misfolded, beta-sheet rich and partially 60 
protease-resistant isoform (PrPSc) of the cellular prion protein (PrPC). In prion diseases misfolded 61 
PrPSc, originating exogenously or spontaneously, is thought to template the structural conversion 62 
of the host-encoded PrPC in an autocatalytic process (1, 2). Intriguingly, a wealth of recent 63 
evidence indicates that proteinaceous seeds serving as self-propagating prion-like agents may 64 
represent a common pathogenetic mechanism in most, if not all, neurodegenerative diseases (3). 65 
Despite their relative rarity, prion diseases show a wide spectrum of clinical and pathological 66 
phenotypes with significant heterogeneity in disease duration, symptomatology and distribution 67 
or type of brain lesions. Current classification of sporadic Creutzfeldt-Jakob disease (sCJD), the 68 
most common human prion disease, includes six major disease phenotypes that strongly correlate 69 
at the molecular level with the genotype at the polymorphic codon 129 (methionine, M, or 70 
valine, V) of the PRNP gene (which encodes for PrPC) and two PrPSc profiles or types (type 1 71 
and type 2) comprising distinctive physicochemical properties such as size after protease 72 
treatment (respectively 21 and 19 kDa) and glycoform ratio (4, 5). Recent studies in animal 73 
models have shown that phenotypic variations among sCJD phenotypes are largely maintained 74 
after transmission into genetically defined hosts, suggesting that different prion strains are the 75 
main cause of this diversity (6–11). Although it is well established that PrPC conversion into 76 
PrPSc involves consistent changes in the secondary structure with part of the α-helical structure 77 
turning into a β-sheet (12, 13), a complete structural characterization of PrPSc has been hampered 78 
by the propensity of the misfolded protein to form highly aggregated and detergent-insoluble 79 
polymers. Consequently, due to the limited data available from direct structural studies (14, 15), 80 
the putative central role of PrPSc tertiary or quaternary structure in determining the molecular 81 
basis of prion strains is not yet clearly demonstrated. Several experimental data, however, 82 
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indirectly support this hypothesis, both in yeast (16) and in mammals. For example, it is largely 83 
believed that the heterogeneity in fragment profile of proteinase K (PK)-digested PrPSc, which 84 
distinguishes at least some of the known prion strains, is the direct consequence of PrPSc 85 
aggregates having distinct conformations (17–21). Similarly, sedimentation profiles and protease 86 
sensitivity have been used as indirect markers of PrPSc structure, and have shown a correlation 87 
with strain-specific transmission properties (22–27). More recently, studies with rodent-adapted, 88 
cloned prion strains, demonstrated that also the conformational stability of PrPSc, measured 89 
indirectly either by inducing a progressive denaturation of the protein with the chaotropic salt 90 
guanidine hydrochloride (GdnHCl) or by exposing the protein to increasing temperatures in the 91 
presence of SDS (sodium dodecyl sulfate), may vary among different strains (28–30). Attempts 92 
have also been made to correlate PrPSc conformational stability to strain specific properties such 93 
as replication rates, although with conflicting, opposite results in murine and hamster models 94 
(28–30).  95 
Overall, despite the wealth of experimental data collected in rodents and some evidence obtained 96 
in humans suggesting that phenotypic diversity is somehow related to distinct PrPSc isoforms 97 
with distinct structure, the conformational spectrum of these isoforms and their relationship to 98 
the issue of prions strains are still poorly understood. In particular, a systematic analysis of the 99 
conformational stability of PrPSc aggregates across the spectrum of human prions CJD is still 100 
lacking. Previous studies focused on the comparison between sCJD subtypes MM1 and MM2 101 
(31–33) or between variant CJD (vCJD) and the most common sCJD type MM1 (34). 102 
Furthermore, only the unfolding induced by GdnHCl was addressed whereas the thermo-stability 103 
of PrPSc has never been explored in CJD. 104 
To add insights to the intriguing relationship among PrPSc molecular types, the conformational 105 
stability of abnormal PrPSc aggregates, and the phenotypic expression of disease, we have 106 
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evaluated both guanidine-induced unfolding and thermo-stability of PrPSc across the whole 107 
spectrum of currently characterized human CJD strains. 108 
 109 
MATERIALS AND METHODS. 110 
Patients and tissues. We studied brain tissues from 60 cases of sCJD and 6 cases of vCJD. sCJD 111 
tissues included the whole spectrum of pure phenotypic variants recognized by current 112 
classification (5): 12 MM1, 9 VV1, 10 MV 2K, 12 VV2, 7 MM2-cortical (MM 2C), and 4 MM2-113 
thalamic (MM 2T). In addition, 6 brains of sCJD MM 1+2C, the most common sCJD subtype 114 
with mixed histopathologic features and the co-occurrence of PrPSc types 1 and 2 were analyzed. 115 
Each sCJD brain was classified as a “pure” or “mixed” type based on the results of 116 
histopathological examination, PrP immunohistochemistry and PrPSc typing in multiple brain 117 
regions, according to Parchi et al (5).  Unfixed brain tissues were obtained at autopsy and kept 118 
frozen at −80 °C until use. All samples used in this study were taken from the cerebral cortex of 119 
the frontal lobe.  120 
Antibodies. The following monoclonal mouse antibodies, immunoreactive with human PrP, 121 
were used: 3F4 at 1:30000, which recognizes residues 106-110 (35), 12B2, at 1:8000, which 122 
binds residues 89-93 (36), and SAF60 at 1:2000, which reacts with residues 157-161 (37). In 123 
addition, the PrPSc type 2-specific polyclonal antibody T2 (1:5000), which binds residues 97-103 124 
(7) and the rabbit antiserum 2301 (1:3000) to human PrP residues 220-231 were used. 125 
Preparation of Total Brain Homogenates (THs). After removing any residual white matter 126 
from the cortical tissue sample, 50-100 mgs of gray matter were homogenized (20%, w/v) in TN-127 
NP40 (100 mM Tris, 130 mM NaCl, 0,5% Nonidet P-40) at pH 7.4 (38) for the guanidine assay 128 
and (10%, w/v) in LB100 (100 mM Tris, 100 mM NaCl, 10 mM EDTA, 0,5% Nonidet P-40, 129 
0,5% sodium deoxycholate) at pH 6.9 (39), for the thermo-solubilisation assay (TSA). In a subset 130 
of experiments having the specific purpose of reproducing a previously published protocol (32), 131 
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a clearing spin of THs at 3000 rpm for 10 minutes was performed. Total protein concentration 132 
was measured using a standard colorimetric method based on bicinchoninic acid (Pierce 133 
Biotechnology, Rockford, IL, USA). 134 
Guanidine induced unfolding/refolding assays. Total brain homogenates (TH) were adjusted 135 
to a protein concentration of  5.5 mg/ml before denaturation. Equal volumes of TH and GdnHCl 136 
solutions ranging from 0 to 4 M (final concentration, ∆[GndHCl]=0.25M) were mixed and 137 
incubated for 1 h at 37°C at 300 rpm (Thermomixer Confort, Eppendorf). After the addition of 138 
PK at a final concentration of 8 U/ml, samples were re-incubated for another 1 h at 37°C at 300 139 
rpm. Protease treatment was terminated by the addition of phenylmethylsulfonyl fluoride 140 
(PMSF) at a final concentration of 3.6 mM. Samples were then precipitated in pre-chilled 141 
methanol for at least 3 hrs at -20° C, re-suspended in sample buffer (final concentration 3% SDS, 142 
4% β-mercaptoethanol, 10% glycerol, 2 mm EDTA, 62.5 mm Tris, pH 6.8) and boiled for 6 143 
minutes. Appropriate GdnHCl working concentrations were obtained from serial dilution of a 144 
8M stock solution (Thermo Scientific Pierce, Protein Biology Products). 145 
To monitor PrPSc refolding, after incubation with GdnHCl, samples were immediately diluted 146 
with 19 volumes of TN-NP40 and subsequently PK-digested at the same working conditions 147 
specified above, precipitated in methanol and re-suspended in sample buffer. To monitor 148 
reproducibility each treatment was repeated twice. 149 
In a subset of samples from 6 MM1 and 6 MM 2C brains we also performed the conformational 150 
stability assay (CSA), after incubation with GdnHCl, according to a previously published 151 
protocol (32). Briefly, after a clearing spin at 3000 rpm for 10 minutes, aliquots of TH were 152 
mixed with aliquots of GdnHCl stock solution to have a final concentration of GdnHCl ranging 153 
from 0 to 4.0 M. After 1.5 hours of incubation at room temperature, samples were precipitated 154 
with 5-fold pre-chilled methanol, centrifuged at 16,000 g for 30 minutes at 4 ºC, and re-155 
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suspended by sonication in 20 μl of LB100 (pH 8.0). Each aliquot was digested with 5 U/ml PK 156 
for 1 hour at 37 ºC. The reaction was stopped with 2 mM PMSF. 157 
Thermo-solubilisation assays. TSA was performed according to Bett and colleagues with minor 158 
modifications (30). Briefly, TH were digested with 8 U/ml PK for 1h at 37°C with mild shaking 159 
(300 rpm). PK digestion was inactivated with PMSF (3,6 mM final concentration). Aliquots were 160 
mixed with an equal volume of loading buffer (final concentration 1,5% SDS, 2% β-161 
mercaptoethanol, 5% glycerol, 1 mM EDTA, 31,25 mM Tris, pH 6.8) and heated to temperatures 162 
ranging from 25°C to 95°C (∆T=10°C) for 6 min with shaking in  a thermomixer at 1000 rpm 163 
before loading. To monitor reproducibility each treatment was repeated twice.  164 
Western blot and quantitative analysis of protein signal. After boiling (or heating treatment) 165 
proteins were resolved in 13% polyacrylamide gels using a medium-sized gel electrophoresis 166 
apparatus (Criterion, Bio-Rad) and transferred to Immobilon-P membranes (Millipore Corp., 167 
Billerica, MA). After blocking in 10% nonfat milk in Tween-Tris-buffered saline, membranes 168 
were incubated with the primary antibody. After four washings in Tween-Tris-buffered saline, 169 
membranes were incubated for 1 h with an anti-mouse or an anti-rabbit secondary antibody 170 
conjugated to horseradish peroxidase (GE Healthcare; working dilution, 1:4000 or 1:3000) and 171 
washed again four times in Tween-Tris-buffered saline. The immunoreactive signal was detected 172 
by enhanced chemiluminescence (Immobilon Western Chemiluminescent HRP Substrate, Merck 173 
Millipore) on a LAS 3000 camera (Fujifilm Corp., Tokyo, Japan). Western blot signals were 174 
measured by densitometry using the software AIDA (Image Data Analyzer v.4.15, Raytest, 175 
Isotopenmessgeraete GmbH, Straubenhardt, Germany).  176 
For guanidine unfolding assay curves were obtained by plotting the percentage of protein 177 
remaining after denaturation and PK-digestion treatments (with respect to the PK-digested but 178 
GndHCl-untreated sample i.e. 0 M, referred as %PrPfold) against the corresponding guanidine 179 
concentration. 180 
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ED50 ([GndHCl]50, e.g. the guanidine concentration needed to unfold 50% of PrPSc) for each 181 
sample was calculated from the equation describing the sigmoidal curve that best fitted the 182 
densitometric data (R2 ≥ 0.95). To compare groups we also considered the percentage of protein 183 
remaining after denaturation plus PK digestion at [GndHCl] = 2 M (referred as %PrPfold2M) and 184 
the percentage of protein detected after refolding plus PK digestion at [GndHCl] = 2M (referred 185 
as %PrPrefold2M). Refolded PrPSc was calculated by means of the formula (R-F)/N, where R = 186 
PrPSc signal detected after GdnHCl incubation, dilution and PK digestion, F = PrPSc signal 187 
detected after GdnHCl incubation without dilution and PK digestion, N = PrPSc signal detected 188 
after PK digestion without GdnHCl addition. 189 
For the TSA we plotted the percentage of protein solubilized after heating treatment (with 190 
respect to the sample treated at 95°C, referred as %PrPScmon) against the corresponding heating 191 
temperature. The ED50 (T50, e.g. the temperature needed to solubilize 50% of PrPSc) for each 192 
sample was calculated from the equation describing the sigmoidal curve that best fitted the data 193 
(R2 ≥ 0.95). To compare groups we also considered the percentage of protein remaining after 194 
treatment at T = 35°C (referred as %PrPScmon35°C) and at T = 75°C (referred as %PrPScmon75°C). 195 
Statistical analyses. Statistical analyses were performed with Sigma Plot 12.5 (Systat Software 196 
Inc., Chicago, IL). One-way analysis of variance (ANOVA) followed by all pairwise multiple 197 
comparison procedures were used to look for significant differences in the chosen parameters 198 
among CJD variants.   199 
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RESULTS 200 
Analysis of molecular mechanisms associated with GndHCl induced unfolding of human 201 
PrPSc. It is well established that the exposure of PrPSc to increasing concentrations of GdnHCl 202 
progressively makes the protein more sensitive to protease digestion. Moreover, while a larger 203 
than 3 M concentration of the chaotropic denaturant irreversibly modifies PrPSc structure and 204 
protease-resistance, milder conditions allow the structural change to be reversible (38). Studies 205 
on PrPSc extracted from Syrian hamster brains also showed that GdnHCl induced unfolding 206 
mainly involves the N-terminal portion of PrPSc, as suggested by the persistence of a PK-207 
resistant, GPI–linked, proteolytic fragment of about 16 kDa over a wide range of GdnHCl 208 
concentrations (40).         209 
Before proceeding with the systematic analysis of the effects of GdnHCl-induced unfolding on 210 
human prions, we carried out preliminary studies aimed to select the most appropriate 211 
experimental conditions. We first compared the effect of PK digestion when performed before or 212 
after GdnHCl dilution, and unexpectedly found that the concentration of the denaturing agent 213 
that is required to fully digest PrP27-30 was significantly lower when PK was added to the 214 
undiluted sample. Indeed, after GdnHCl serial dilution we noticed a rapid partial recovery of 215 
PrPSc protease-resistance. Only treatments with GdnHCl concentrations of 3.5-4 M irreversibly 216 
denatured the protein after solubilisation and made it completely PK-sensitive (Fig. 1). Given the 217 
observed rapid recovery of PrPSc original conformation and the notion that PK is not 218 
significantly inhibited by GdnHCl even at a relatively high concentration (41, 42), we chose to 219 
perform PK digestions in the undiluted denaturing agent (i.e. PK hydrolysis in buffer containing 220 
GdnHCl). To select the most appropriate antibody for monitoring the effect of GdnHCl on PrPSc 221 
PK-sensitivity, we compared the 3F4 antibody, which recognizes a central PrP epitope (35), with 222 
antibodies against distinct C-terminal epitopes, which are known to recognize PrPSc truncated 223 
fragments, in addition to PrPSc 27-30 (20). In contrast to 3F4, which only revealed PrPSc 27-30, 224 
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C-terminal antibodies also showed variable amounts of a 18 kDa fragment, consistent with PrPC-225 
C1 (43), and of a 7-8 kDa fragment, likely generated by endogenous proteolysis of PrPC during 226 
the one hour incubation at 37°C preceding PK-digestion. Given the presence of these fragments 227 
in untreated control samples and the lack of any correlation between the relative amount of such 228 
fragments and GdnHCl concentration, we concluded that: (i) the generation of these PrPSc 229 
fragments is not denaturation-dependent, (ii) central antibodies such as 3F4 are more appropriate 230 
than C-terminal antibodies to study the effect of GndHCl on PrPSc structure.   231 
PrPSc isolates associated with distinct human prion strains show similar denaturation 232 
curves after exposure to GndHCl. Guanidine denaturation curves showed a similar sigmoid 233 
profile in all CJD samples analysed (Fig. 2A, B). The curve that best fitted the data (R2 ≥ 0.95) 234 
was a four parameter sigmoid equation. Calculated values for [GdnHCl]50 ranged from 0,86 M 235 
(sCJDVV2) to 1,03 M (sCJDMM 2T) with no statistically significant differences among CJD 236 
types (Fig. 2C). A similar value trend was obtained by calculating the percentage of detectable 237 
PrPSc signal at a GndHCl concentration of 2 M (%PrPfold2M) (Fig. 2D). 238 
To further look for strain-specific effects of GdnHCl, we also calculated the percentage of 239 
refolded PrPSc (%PrPrefold2M; see methods) at a given, intermediate GdnHCl concentration (2 M). 240 
In agreement with our preliminary screening, PrPSc renaturation occurred in all groups analysed. 241 
Calculated values ranged from 14% to 29%, but, again, with no statistically significant 242 
differences among CJD types (Table 1). 243 
In order to exclude that the divergent results previously obtained by Cali et al. (32) on MM1 and 244 
MM 2C prions would only reflect a difference in the methodology used, we also repeated the 245 
experiments in a subgroup of samples following their protocol (32). The results obtained 246 
confirmed the lack of remarkable differences between MM1 and MM 2C (Fig. 3). In particular, 247 
the [GdnHCl]50 values obtained in both groups (1.98 ± 0.05 M and 1.87 ± 0.09 M, respectively) 248 
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were intermediate between those previously observed in MM 2C (2.76 M) and MM1 (1.42 M) 249 
(32).  250 
PrPSc aggregates associated with distinct human prion strains show a divergent response to 251 
thermal solubilisation. It has been shown that the exposure of PK digested PrPSc to a thermal 252 
gradient in the presence of SDS induces a progressive “solubilisation” of protein aggregates 253 
which can be measured by a semi-quantitative immunoblot analysis of monomeric PrPSc (30). By 254 
applying this experimental approach to the full spectrum of human prions, we found that, at 255 
variance with the GdnHCl assay, the specific profile of the calculated solubilisation curve and of 256 
T50, %PrPScmon35°C and %PrPScmon75°C associated values, varied significantly according to the 257 
CJD type (Fig. 4 and 5). Overall, while PrPSc aggregates in sCJD VV1, and to a lesser extent in 258 
MM 2T or MM 2C showed a relatively high sensitivity to thermal solubilisation, those associated 259 
with MM1, VV2, and MV 2K were significantly more resistant. Hence, on the basis of the 260 
analysed parameters, CJD types could be grossly classified in three groups: resistant (MM1, 261 
VV2, MV2K), sensitive (vCJD, MM2C, and MM2T) and highly sensitive (VV1) to thermal 262 
solubilisation. A further heterogeneity was observed within the sensitive group with vCJD prions 263 
showing a more “resistant” profile at the highest temperatures in comparison to MM 2T and MM 264 
2C (Fig. 5D). 265 
To exclude the possibility that the observed heterogeneity in the thermo-stability of PrPSc 266 
aggregates derives from conformational changes that are limited to the 3F4 binding region, we 267 
re-analyzed a subgroup of MM1 and VV1 samples using the mAb SAF60. The thermo-268 
solubilisation curves calculated from the immunoblots labeled with SAF60 fully matched those 269 
obtained using 3F4 (Fig. 4). In addition, the 13 kDa C-terminal fragment that is visualized by this 270 
antibody (20) in addition to PrP27-30, showed a solubilization kinetics that paralleled that of 271 
PrP27-30 in each CJD type (e.g. more thermostable in MM1 than in VV1) (Fig. 4). The latter 272 
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observation strongly suggests that PrPSc aggregates in CJD MM1 and VV1 include both 273 
fragments.   274 
Finally we plotted the solubilisation curves for each of the three PrPSc glycoforms and found a 275 
similar thermo-solubilisation kinetics for each of them with only a minor trend toward a 276 
preferential solubilisation of the di- and monoglycosylated forms (data not shown).  277 
PrPSc types co-occurrence in mixed sCJD phenotypes does not alter/affect thermal 278 
solubilisation properties of coexisting isoforms. It is well known that PrPSc types 1 and 2 279 
coexist within the same brain in about 35% of sCJD cases (5). Accordingly, mixed phenotypes 280 
have been considered as distinct subtypes in current sCJD classification (44). However, the 281 
critical question of whether the brain co-occurrence of PrPSc types simply reflects the neutral 282 
coexistence of two prion strains forming independent protein aggregates, or in contrast represents 283 
interacting strains forming mixed aggregates with distinct physicochemical properties, remains 284 
unanswered. To investigate this issue we selected 6 cortical samples from sCJD MM1+2C 285 
containing a significant amount of both types (e.g. with the less represented type 2 being between 286 
30 and 50% of the total PrPSc signal). We calculated the solubilisation curves for these samples 287 
using three different antibodies. More specifically, we monitored the solubilisation trend of the 288 
two PrPSc types simultaneously using 3F4, and analysed PrPSc types 1 and 2 separately, despite 289 
their co-occurrence, with the type-specific antibodies 12B2 and T2 (Fig. 6A). Remarkably, the 290 
curves generated with the 12B2 and T2 antibodies fully matched or paralleled very closely those 291 
of the corresponding pure phenotype (Fig. 6B). Accordingly, no significant statistical differences 292 
were observed in the calculated T50, %PrPScmon35°C and %PrPScmon75°C values between mixed 293 
and pure samples for both PrPSc types 1 and 2. Moreover, statistical analysis confirmed the 294 
differences between PrPSc types 1 and 2 when analysed in mixed samples using the type-specific 295 
antibodies (Fig. 6C, D, E). 296 
 297 
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DISCUSSION. 298 
The analysis of GdnHCl-induced unfolding by either the conformation-dependent immunoassay 299 
(CDI), which measures the extent of epitope exposure, or the conformational stability assay 300 
(CSA), which, instead, monitors the progressive loss of PK-resistance after exposure to 301 
increasing concentrations of GdnHCl, has been extensively applied to the study of PrPSc 302 
molecules. CDI analysis of PrPSc unfolding in different murine prion strains yielded unique 303 
binding profiles, suggesting that each strain is related to a specific PrPSc conformation (45). 304 
Similarly, the stability of PrPSc aggregates measured by CSA or by a thermal stability assay 305 
(TSA) was found strain-dependent and inversely correlated with the capacity to induce a rapidly 306 
lethal disease in murine models (30). At variance with experimentally cloned rodent prion 307 
strains, however, less numerous and less conclusive data have been obtained with PrPSc 308 
preparations extracted from naturally occurring prion diseases, especially in humans. In the few 309 
studies performed to date, sCJDMM1 PrPSc was shown to be more stable than MM 2C PrPSc by 310 
both CDI and CSA, and MM1 PrPSc to have a moderately higher stability than vCJD PrPSc by 311 
CDI (32–34). In the present study, we have carried out the first systematic analysis of PrPSc 312 
conformational stability in a large series of brain samples across the whole spectrum of human 313 
sCJD and vCJD prions. Our results failed to reveal significant strain-specific differences in the 314 
GdnHCl-denaturation curve of PrPSc aggregates. Thus, despite the limitations related to the 315 
methodology being rather crude, the data suggest that the intermolecular interactions modulating 316 
the divergent PrPSc aggregation propensity among CJD types (27) are not strongly targeted by 317 
GdnHCl.        318 
As far as CSA is concerned, we introduced some variations in the protocol to minimize PrPSc 319 
refolding, namely by performing the PK digestion step without removing or diluting GdnHCl. 320 
Given that PrPSc refolding is paralleled by an increase in PK-resistance of the protein, it is 321 
expected that GndHCl dilution before PK treatment would increase the calculated [GndHCl]50, 322 
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and, indeed, [GndHCl]50 values in previous studies were greater than 1.5 M, whereas our mean 323 
values ranged from 0.86 M to 1.03 M. In order to exclude the possibility that the discrepant 324 
results with a previous study (32) concerning MM1 and MM 2C prions, could be due to a 325 
difference in the methodology used, we repeated the study of GndHCl induced PrPSc unfolding 326 
using the original protocol (32). While, as expected, the changed procedure led to an increase in 327 
[GndHCl]50 values, the results confirmed the lack of significant differences in the GdnHCl-328 
denaturation curve between MM1 and MM 2C sCJD prions.   329 
Another approach that has been used to characterize prion strains in mice (30, 46), although 330 
never applied to the study of CJD prions, focuses on the denaturing effect of heating in the 331 
presence of SDS. Likewise GndHCl, this assay likely mainly measures the propensity of PK-332 
digested PrPSc aggregates to depolymerize. At variance with GdnHCl, however, the exposure to 333 
increasing temperatures revealed significantly different responses among sCJD types with MM1, 334 
VV2 and MV 2K PrPSc mainly forming stable, highly resistant aggregates, the VV1 type 335 
comprising highly unstable aggregates that easily dissolve at a relatively low temperature, and 336 
MM 2C, MM 2T and vCJD prions exhibiting an intermediate behavior. 337 
The relatively high level of PrPSc that is solubilized at relatively low temperatures in some prion 338 
types is intriguing, and may suggest that these agents comprise different forms of PrPSc. 339 
Consistently, an increasing number of studies support the idea that a variable proportion of 340 
abnormal PrP is made by a soluble, poorly aggregated and fairly PK-sensitive form, although its 341 
specific role and relevance for disease pathogenesis remain controversial (27, 47). Our approach, 342 
focusing on PK-treated PrPSc, did not allow us to address in depth the issue of the influence of 343 
this putative “fully PK-sensitive PrPSc” on thermostability profile; nevertheless the lack of an 344 
obvious correlation between sedimentation profile (as determined in 27), and thermostability 345 
(present work) of PK-treated PrPSc suggest that factors other than size also contribute to the 346 
thermo-stability of PrPSc aggregates in CJD.  347 
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The present results, when combined with the growing knowledge on human prion strains, 348 
provide novel insights into the relationships between the physicochemical properties of PrPSc 349 
aggregates and disease characteristics such as incidence, phenotypic expression, and 350 
transmission properties (5,7,10,11,48-51). In particular, PrPSc thermo-stability appears to largely, 351 
although not entirely, correlate with prion replication efficiency expressed by either attack rate 352 
and incubation time after experimental transmission in the most compatible host genotype or by 353 
relative incidence and duration of clinical disease (Table 2). In this regard, the comparison 354 
between VV2 and VV1 human prions appears to be particularly illustrative. Indeed, when 355 
compared to VV1, VV2 prions are more common, cause a more rapid disease (5), are more 356 
readily transmissible (10), and produce PrPSc aggregates with a higher thermo-stability, PK-357 
resistance, and aggregation propensity (Table 2) (27). Thus, at variance with earlier observations 358 
in murine and yeast prions [PSI+], suggesting that a low PrPSc aggregate stability, by favoring 359 
the fragmentation of PrPSc aggregates, would result in a higher prion replication rate, in humans 360 
the thermo-stability of PrPSc seems to positively correlate with disease severity and “virulence” 361 
in the most compatible host genotype. It is noteworthy that our observation is also consistent 362 
with data obtained with hamster-adapted prion strains, showing that short incubation period 363 
strains are characterized by a higher conformational stability of PrPSc and a more efficient 364 
replication (28, 29). 365 
Our results also reveal a relatively high thermo-stability, comparable to that of VV2, for MM1 366 
and MV 2K prions. For the latter, the results are consistent with data from transmission studies 367 
showing that sCJD VV2 and MV 2K are linked to the same prion strain (V2) (9), whereas the 368 
result obtained with MM1 further confirms the positive correlation between PrPSc thermo-369 
stability and strain “virulence” (Table 2). However, the degree of PK-resistance of PrPSc 370 
aggregates in MM1 is not as high as in VV2 and MV 2K (27), indicating that the two variables 371 
are not necessarily directly correlated (Table 2). Our findings that PrPSc aggregates in vCJD 372 
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show a very high resistance to PK digestion (27) despite being less thermo-stable than those from 373 
sCJD MM1 prions also support this conclusion. It has been suggested that PK itself may act as 374 
disaggregating agent by eliminating PrP monomers (48) and thus changing the equilibrium 375 
between monomers and polymers in favor of monomers. Likewise, GndHCl or heating exposure 376 
also act as disaggregating agent. Thus, the divergent response we obtained using these three 377 
methods suggest that propensity of PrPSc to disaggregate is significantly affected by the type of 378 
treatment, which is also in line with evidence indicating that temperature and GdnHCl destabilize 379 
the folded structure of proteins by means of distinct molecular mechanisms (52–55). 380 
In addition to the analyses on pure phenotypes, we performed TSA on six cases with a mixed 381 
phenotype, carrying MM at PRNP codon 129, and showing the co-occurrence of PrPSc types 1 382 
and 2 in the brain. In particular, we addressed the unsolved question of whether the brain co-383 
occurrence of PrPSc types simply reflects the neutral coexistence of two prion strains forming 384 
independent protein aggregates or, in contrast, interacting strains form mixed aggregates with 385 
novel specific properties. At variance with the findings of a previous study (32) arguing that the 386 
co-existence of types 1 and 2 in the same anatomical region may confer special conformational 387 
characteristics to the mixed PrPSc type aggregate, the results we obtained using type-specific 388 
antibodies support the former hypothesis. Indeed, properties of each individual type, when co-389 
existing, exactly fit those of the corresponding pure type, suggesting a lack of interaction 390 
between the two PrPSc types. The discrepant results between the two studies are difficult to 391 
explain given that they were obtained using different approaches (CSA vs TSA). Unfortunately, 392 
we could not address the issue further, since we failed to reveal a significant difference in PrPSc 393 
conformational stability between the pure MM1 and MM 2C types using CSA. 394 
    395 
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FIGURE LEGENDS 573 
FIGURE 1. Monitoring PrPSc refolding after GdnHCl-induced unfolding. Samples were 574 
exposed to increasing concentrations of GdnHCl and then PK-digested immediately (upper 575 
panel) or after GdnHCl dilution (lower panel). PrPSc refolding is detected after GdnHCl dilution 576 
in samples exposed up to 2.5M GdnHCl. 577 
 578 
FIGURE 2. GdnHCl-induced unfolding demonstrate a similar conformational stability of 579 
PrPSc aggregates across the spectrum of CJD prions. Brain homogenates were treated with 580 
increasing concentrations of GdnHCl and digested with PK, followed by SDS-PAGE and 581 
immunoblotting. Membranes were incubated with the primary antibody 3F4. (A) Representative 582 
immunoblots showing similar denaturation profiles among the seven CJD types analyzed. (B) 583 
Plots of GndHCl-induced PrPSc unfolding for each sCJD type and vCJD. The y axis reports the 584 
percentage of folded PrPSc (e.g. percentage of PK-resistant PrPSc) relative to the untreated 585 
sample. Symbols represent data expressed as mean ± standard deviation, lines the sigmoid curves 586 
that best fit the data. (C) [GdnHCl]50 values for each CJD type, expressed as mean ± standard 587 
deviation, indicating the GdnHCl molar concentration necessary to unfold 50% of untreated 588 
PrPSc. (D) Percentage of folded PrPSc at 2 M GndHCl, expressed as mean ± standard deviation. 589 
 590 
FIGURE 3. Conformational stability assay shows only subtle differences between 591 
sCJDMM1 and MM 2C prions. (A) Representative immunoblots of CSA, performed according 592 
to the protocol described by Cali et al. (32) on MM1 and MM 2C prions. Membranes were 593 
incubated with the primary antibody 3F4. (B) Plots of GndHCl-induced PrPSc unfolding data sets 594 
for MM1 and MM 2C prions. The y axis reports the percentage of folded PrPSc (e.g. percentage 595 
of PK-resistant PrPSc) relative to the untreated sample. Symbols represent data expressed as 596 
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mean ± standard deviation, lines the sigmoid curves (s) that best fit the data. [GdnHCl]50 is 597 
expressed as mean ± standard deviation. 598 
 599 
FIGURE 4. CJD types show remarkable differences in the thermal stability of PK-digested 600 
PrPSc aggregates. PK-digested brain samples were subjected to increasing temperatures, 601 
followed by SDS-PAGE and immunoblotting. Representative immunoblots for each CJD type, 602 
probed with the primary antibodies 3F4 (all types) and SAF60 (only for sCJDMM1 and VV1, as 603 
labeled) are shown. 604 
 605 
FIGURE 5. Comparative analysis of the divergent thermal stability of CJD prions. (A) 606 
Plots of TSA data sets for each sCJD type and vCJD. The y axis reports the percentage of PrPSc 607 
in the monomeric state at each tested temperature relative to the sample treated at 95 °C. 608 
Symbols represent the data expressed as mean ± standard deviation, lines the sigmoid curves (s) 609 
that best fit the data. (B) T50 values for each tested CJD group, expressed as mean ± standard 610 
deviation, indicating the temperature necessary to unfold 50% of PrPSc relative to the sample 611 
treated at 95°C. N.E. = not estimable. (C) Percentage of monomeric PrPSc at 35 °C expressed as 612 
mean ± standard deviation. (D) Percentage of monomeric PrPSc at 75 °C expressed as mean ± 613 
standard deviation. In panels (B-D) the triple asterisk (***) indicates a p<0.001 for all pairwise 614 
multiple comparisons between the groups; the double asterisk (**) indicates a p<0.001 for all 615 
pairwise multiple comparisons with the exception of: (B) vCJD vs MM 2C (p<0.005) and vCJD 616 
vs MM 2T (p=0.184, not significant); (C) VV2 vs MM 2T (p<0.002), and VV1 vs vCJD 617 
(p<0.005); (D) MM 2C vs vCJD (p<0.005), VV1 vs vCJD (p=0.016), and MM 2T vs vCJD 618 
(p=0.029). 619 
 620 
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FIGURE 6. In vivo co-occurring MM1 and MM 2C prions maintain the distinctive thermo-621 
stability of the corresponding pure CJD type. PK-digested brain samples were subjected to 622 
increasing temperatures, followed by SDS-PAGE and immunoblotting. (A) Representative 623 
immunoblots of TSA performed on a MM1+2C sample, probed with primary antibodies 3F4, 624 
12B2 and T2. (B) Plots of temperature solubility assay data sets for PrPSc types 1 and 2, when 625 
co-occurring (MM1+2C) are compared to those of the corresponding pure type (MM1 and MM 626 
2C respectively). Type-specific antibodies 12B2 and T2 have been used to obtain accurate 627 
separate measurement of type 1 and type 2 signals in mixed samples. Symbols represent data 628 
expressed as mean ± standard deviation, lines the sigmoid curves that best fit the data. (C) 629 
Comparison of T50 values between pure and mixed variants. The triple asterisk (***) indicates a 630 
statistically significant differences between groups at p<0.001. (D) Comparison of the percentage 631 
of monomeric PrPSc at 35 °C between pure and mixed variants. The double asterisk (**) 632 
indicates a p<0.05 between groups with the exception of MM1 vs type 2 PrPSc (not significant). 633 
(E) Comparison of the percentage of monomeric PrPSc at 75 °C between pure and mixed 634 
variants. The triple asterisk (***) indicates a p<0.001 between groups.  635 
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TABLE 1. Mean values of %PrPScrefold2M for each CJD typea 636 
CJD type %PrPScrefold2M 
  
MM1 24.06 ± 11.69 
VV2 21.32 ± 6.02 
MV 2K 19.72 ± 15.53 
MM 2C 24.53 ± 9.69 
MM 2T 21.07 ± 10.73 
VV1 11.19 ± 5.18 
  
vCJD 17.60 ± 10.25 
aAll parameters are expressed as mean ± standard deviation; no statistically significant 637 
differences were observed among CJD types. 638 
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TABLE 2. CJD strains: Comparison of epidemiological and clinical data, results of experimental transmission, and biochemical PrPSc 639 
properties. 640 
CJD type Strain  Incidence as % of total sCJD cases (ref.) 
Mean disease 
duration in 
months (ref.) 
Attack rate in % 
(ref.)a,b 
Incubation 
time in days 
(ref.)a,b 
T50 (°C) 
(present 
work) 
PK resistance 
ED50 (U/ml)c 
(from ref. 27) 
VV2 
V2 
15 (5) 
6.3d (5) 
100 (7, 10, 48) 274 ± 4 (10) 302 ± 9 (7, 48) 82.05 ± 3.70 4.137 ± 3.562 
MV 2K 8 (5) 100 (10, 48) 288 ± 3 (10) 329 ± 3 (48) 79.48 ± 3.63 1.407 ± 0.892 
MM1 M1 40 (5) 4.0 (5) 100 (7, 10, 48) 446 ± 3 (10) 467 ± 24 (7, 48) 79.66 ± 2.32 0.093 ± 0.068 
vCJD BSE rare (49) 14  (49) 83 (50) 100 (50) 
540 ± 41 (50) 
668 ± 22 (50) 65.26 ± 3.19 5.192 ± 2.378 
MM 2T M 2T 1 (5) 15.5 (5) 93 (11) 535 ± 32 (11) 59.41 ± 6.04  0.134 ± 0.089 
VV1 V1 1 (5) 15.3 (5) 50 (10) 568 ± 0 (10) < 25 0.034 ± 0.028 
MM 2C M 2C 1 (5) 20.0 (5) 0 (10, 11, 48, 51) - (10, 11, 48, 51) 57.11 ± 5.96 0.276 ± 0.210 
a Data are from PrP-humanized knock-in mice expressing normal levels of human PrPC. 641 
 b Data for each strain refer to those obtained in recipient animals carrying the most compatible PRNP 129 genotype. 642 
c ED50 is the PK concentration needed to digest 50% of PrPSc.  643 
dThe reported mean disease duration only refers to VV2, the group with the most compatible 129 genotype to the V2 strain.644 
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